Delivery Order SPE2DB24D3015-SPE2DB25FGAQF
- Not listed
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency (DLA) awarded a $8,495.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of July 21, 2025. This non-set-aside contract was competitively awarded on July 18, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal healthcare needs, specifically for diabetes...
- The Defense Logistics Agency awarded a delivery order valued at $1,150.32 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on August 15, 2025, with an ultimate completion date of August 18, 2025, represents a firm fixed-price procurement with no set-aside designation. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, valued at $1,257.27 with a firm fixed price structure. The award, issued on July 30, 2025, represents a non-competitive delivery order with a completion date of July 31, 2025. This contract is a child award executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 comprehensive...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,170.50 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This firm fixed price, competitively awarded contract was issued on July 25, 2025, with an ultimate completion date of July 28, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in Conshohocken, PA. The...
- The Defense Logistics Agency awarded a $2,108.70 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,661.10 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $2,289.71 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAQFDelivery Order
The Defense Logistics Agency awarded a $1,247.08 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of August 19, 2025. This firm fixed-price contract represents a non-set-aside award issued on August 18, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the distributor to supply medications and medical commodities to military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare systems. The company was competitively selected through open competition to supply this diabetes medication as part of its ongoing role as a prime pharmaceutical vendor under the DLA contract. This delivery order exemplifies the company's extensive portfolio of medical product deliveries across multiple therapeutic domains, from specialty medications to vaccines and medical supplies, demonstrating its capability to fulfill varied federal procurement requirements through the flexible IDC vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/18/25 |